Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
Background: Metastatic triple-negative breast cancer (mTNBC) is incurable. A key treatment goal is providing palliation while maintaining patients' health-related quality of life (HRQoL). IMpassion130 demonstrated progression-free survival benefit with atezolizumab + nab-paclitaxel (A + nP) ver...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 February 2020
|
| In: |
Annals of oncology
Year: 2020, Jahrgang: 31, Heft: 5, Pages: 582-589 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2020.02.003 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2020.02.003
|
| Verfasserangaben: | S. Adams, V. Dieras, C.H. Barrios, E.P. Winer, A. Schneeweiss, H. Iwata, S. Loi, S. Patel, V. Henschel, S.Y. Chui, H.S. Rugo, L.A. Emens, P. Schmid |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1724847414 | ||
| 003 | DE-627 | ||
| 005 | 20230426103246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200715s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2020.02.003 |2 doi | |
| 035 | |a (DE-627)1724847414 | ||
| 035 | |a (DE-599)KXP1724847414 | ||
| 035 | |a (OCoLC)1341345399 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Adams, Sylvia |e VerfasserIn |0 (DE-588)1213844738 |0 (DE-627)1724849166 |4 aut | |
| 245 | 1 | 0 | |a Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer |c S. Adams, V. Dieras, C.H. Barrios, E.P. Winer, A. Schneeweiss, H. Iwata, S. Loi, S. Patel, V. Henschel, S.Y. Chui, H.S. Rugo, L.A. Emens, P. Schmid |
| 264 | 1 | |c 20 February 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.07.2020 | ||
| 520 | |a Background: Metastatic triple-negative breast cancer (mTNBC) is incurable. A key treatment goal is providing palliation while maintaining patients' health-related quality of life (HRQoL). IMpassion130 demonstrated progression-free survival benefit with atezolizumab + nab-paclitaxel (A + nP) versus placebo + nab-paclitaxel (Pl + nP) in first-line treatment of mTNBC patients with programmed death-ligand 1 positive (PD-L1+) tumors. We report data on patient-reported outcomes (PROs), which capture patient perspectives of treatment. Patients and methods: Patients with untreated advanced or mTNBC received atezolizumab (840 mg) or placebo every 2 weeks in combination with nab-paclitaxel (100 mg/m(2)) on days 1, 8, and 15 of each 28-day cycle until progression or intolerance. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and its Breast Cancer Module (QLQ-BR23) on day 1 of each cycle, at end of treatment, and every 4 weeks during 1 year of follow-up. Time-to-deterioration (TTD) in HRQoL (first >= 10-point decrease from baseline lasting two cycles) was a secondary end point. Exploratory end points included TTD in functioning and mean and mean change from baseline scores in HRQoL, functioning, and disease- and treatment-related symptoms. Results: Baseline completion of PROs was 92% (QLQ-C30) and 89% (QLQ-BR23) and remained >80% through cycle 20 in intent-to-treat (ITT) and PD-L1+ patients. No differences between arms in median TTD in PD-L1+ patients were observed for HRQoL {hazard ratio (HR) 0.94 [95% confidence interval (CI) 0.69-1.28]} or physical [HR 1.02 (95% CI 0.76-1.37)] or role [HR 0.77 (95% CI 0.57-1.04)] functioning. Mean baseline scores for A + nP versus Pl + nP for HRQoL (67.5 versus 65.0) and physical (82.8 versus 79.4) and role (73.7 versus 71.7) functioning were comparable between arms and throughout the course of treatment, with no clinically meaningful (>= 10 point) changes from baseline until patients discontinued treatment. No differences in clinically meaningful worsening in treatment symptoms (fatigue, diarrhea, or nausea/vomiting) were observed between arms. Results in ITT patients were similar. Conclusions: A + nP as first-line treatment for mTNBC delayed progression without compromising patients' day-to-day functioning or HRQoL or worsening treatment symptoms. | ||
| 650 | 4 | |a atezolizumab | |
| 650 | 4 | |a clinical-practice guidelines | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a european-organization | |
| 650 | 4 | |a health-related quality of life | |
| 650 | 4 | |a nab-paclitaxel | |
| 650 | 4 | |a patient function | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a qlq-c30 | |
| 650 | 4 | |a triple-negative breast cancer | |
| 700 | 1 | |a Dieras, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barrios, C. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Winer, E. P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Iwata, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loi, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Patel, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Henschel, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chui, S. Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rugo, H. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Emens, L. A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid, P. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 31(2020), 5, Seite 582-589 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer |
| 773 | 1 | 8 | |g volume:31 |g year:2020 |g number:5 |g pages:582-589 |g extent:8 |a Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2020.02.003 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200715 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 5 | ||
| 999 | |a KXP-PPN1724847414 |e 3724553471 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["S. Adams, V. Dieras, C.H. Barrios, E.P. Winer, A. Schneeweiss, H. Iwata, S. Loi, S. Patel, V. Henschel, S.Y. Chui, H.S. Rugo, L.A. Emens, P. Schmid"]},"note":["Gesehen am 15.07.2020"],"person":[{"role":"aut","family":"Adams","display":"Adams, Sylvia","given":"Sylvia"},{"given":"V.","display":"Dieras, V.","family":"Dieras","role":"aut"},{"role":"aut","family":"Barrios","display":"Barrios, C. H.","given":"C. H."},{"role":"aut","family":"Winer","given":"E. P.","display":"Winer, E. P."},{"given":"Andreas","display":"Schneeweiss, Andreas","role":"aut","family":"Schneeweiss"},{"role":"aut","family":"Iwata","display":"Iwata, H.","given":"H."},{"display":"Loi, S.","given":"S.","role":"aut","family":"Loi"},{"display":"Patel, S.","given":"S.","role":"aut","family":"Patel"},{"display":"Henschel, V.","given":"V.","role":"aut","family":"Henschel"},{"role":"aut","family":"Chui","given":"S. Y.","display":"Chui, S. Y."},{"given":"H. S.","display":"Rugo, H. S.","role":"aut","family":"Rugo"},{"family":"Emens","role":"aut","given":"L. A.","display":"Emens, L. A."},{"given":"P.","display":"Schmid, P.","family":"Schmid","role":"aut"}],"recId":"1724847414","physDesc":[{"extent":"8 S."}],"id":{"eki":["1724847414"],"doi":["10.1016/j.annonc.2020.02.003"]},"title":[{"title_sort":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"20 February 2020","dateIssuedKey":"2020"}],"relHost":[{"disp":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancerAnnals of oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"pubHistory":["1.1990 -"],"language":["eng"],"part":{"volume":"31","year":"2020","text":"31(2020), 5, Seite 582-589","pages":"582-589","extent":"8","issue":"5"},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press"}],"title":[{"title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology"}],"id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796"}]} | ||
| SRT | |a ADAMSSYLVIPATIENTREP2020 | ||